Martin Gengenbacher

List of Publications by Year
in descending order

#	Article	IF	Citations
1	Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0140021.	3.2	8
2	<i>In Vitro</i> Resistance against DNA Gyrase Inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus. Microbiology Spectrum, 2022, 10, e0132121.	3.0	11
3	A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study. Antimicrobial Agents and Chemotherapy, 2022, 66, aac0221221.	3.2	13
4	CinA mediates multidrug tolerance in Mycobacterium tuberculosis. Nature Communications, 2022, 13, 2203.	12.8	22
5	A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Antimycobacterial Activity. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	23
6	Potency boost of a <i>Mycobacterium tuberculosis</i> dihydrofolate reductase inhibitor by multienzyme F ₄₂₀ H ₂ -dependent reduction. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	9
7	Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2021, 65, e0067621.	3.2	14
8	Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits. Antimicrobial Agents and Chemotherapy, 2021, 65, e0002421.	3.2	12
9	Epetraborole Is Active against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2021, 65, e0115621.	3.2	17
10	Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0050621.	3.2	12
11	A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2021, 65, e0151421.	3.2	10
12	Rifabutin Is Active against Mycobacterium abscessus in Mice. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	59
13	Indole Propionic Acid, an Unusual Antibiotic Produced by the Gut Microbiota, With Anti-inflammatory and Antioxidant Properties. Frontiers in Microbiology, 2020, 11, 575586.	3.5	49
14	Pyrazinamide triggers degradation of its target aspartate decarboxylase. Nature Communications, 2020, 11, 1661.	12.8	66
15	Tissue Distribution of Doxycycline in Animal Models of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	20
16	TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	34
17	Gut Microbiota Metabolite Indole Propionic Acid Targets Tryptophan Biosynthesis in <i>Mycobacterium tuberculosis</i>. MBio, 2019, 10, .	4.1	63
18	Humanized Mouse Model Mimicking Pathology of Human Tuberculosis for in vivo Evaluation of Drug Regimens. Frontiers in Immunology, 2019, 10, 89.	4.8	23

#	Article	IF	Citations
19	Whole-Cell Screen of Fragment Library Identifies Gut Microbiota Metabolite Indole Propionic Acid as Antitubercular. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	49
20	Novel Acetamide Indirectly Targets Mycobacterial Transporter MmpL3 by Proton Motive Force Disruption. Frontiers in Microbiology, 2018, 9, 2960.	3.5	28
21	The proteobacterial species <i>Burkholderia pseudomallei</i> produces ergothioneine, which enhances virulence in mammalian infection. FASEB Journal, 2018, 32, 6395-6409.	0.5	19
22	The Mycobacterial Membrane: A Novel Target Space for Anti-tubercular Drugs. Frontiers in Microbiology, 2018, 9, 1627.	3.5	40
23	Impact of immunopathology on the antituberculous activity of pyrazinamide. Journal of Experimental Medicine, 2018, 215, 1975-1986.	8.5	29
24	Indolyl Azaspiroketal Mannich Bases Are Potent Antimycobacterial Agents with Selective Membrane Permeabilizing Effects and in Vivo Activity. Journal of Medicinal Chemistry, 2018, 61, 5733-5750.	6.4	28
25	Rifabutin Is Active against Mycobacterium abscessus Complex. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	119
26	Draft Genome Sequence of Mycobacterium abscessus Bamboo. Genome Announcements, 2017, 5, .	0.8	32
27	Integration of Metabolomics and Transcriptomics Reveals a Complex Diet of Mycobacterium tuberculosis during Early Macrophage Infection. MSystems, 2017, 2, .	3.8	112
28	NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans. Scientific Reports, 2017, 7, 8853.	3.3	22
29	BCG â€" old workhorse, new skills. Current Opinion in Immunology, 2017, 47, 8-16.	5.5	33
30	Draft Genome Sequence of Mycobacterium avium 11. Genome Announcements, 2017, 5, .	0.8	7
31	Mild Nutrient Starvation Triggers the Development of a Small-Cell Survival Morphotype in Mycobacteria. Frontiers in Microbiology, 2016, 7, 947.	3.5	49
32	Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis. ACS Infectious Diseases, 2016, 2, 616-626.	3.8	83
33	Developmental transcriptome of resting cell formation in Mycobacterium smegmatis. BMC Genomics, 2016, 17, 837.	2.8	30
34	Deletion of <i>nuoG</i> from the Vaccine Candidate Mycobacterium bovis BCG Î" <i>ureC</i> :: <i>hly</i> Improves Protection against Tuberculosis. MBio, 2016, 7, .	4.1	62
35	Post-exposure vaccination with the vaccine candidate Bacillus Calmetteâ€"GuÃ©rin Î"ureC::hly induces superior protection in a mouse model of subclinical tuberculosis. Microbes and Infection, 2016, 18, 364-368.	1.9	19
36	Antibacterial Drug Discovery: Doing It Right. Chemistry and Biology, 2015, 22, 5-6.	6.0	9

#	Article	IF	Citations
37	Absolute Proteome Composition and Dynamics during Dormancy and Resuscitation of Mycobacterium tuberculosis. Cell Host and Microbe, 2015, 18, 96-108.	11.0	229
38	Comprehensive insights into transcriptional adaptation of intracellular mycobacteria by microbe-enriched dual RNA sequencing. BMC Genomics, 2015, 16, 34.	2.8	90
39	The Recombinant BCG Î”<i>ureC::hly</i>Vaccine Targets the AIM2 Inflammasome to Induce Autophagy and Inflammation. Journal of Infectious Diseases, 2015, 211, 1831-1841.	4.0	74
40	The BCG replacement vaccine VPM1002: from drawing board to clinical trial. Expert Review of Vaccines, 2014, 13, 619-630.	4.4	62
41	Dietary Pyridoxine Controls Efficacy of Vitamin B ₆ -Auxotrophic Tuberculosis Vaccine Bacillus Calmette-GuÃ©rin Î” <i>ureC</i> :: <i>hly</i> Î” <i>pdx1</i> in Mice. MBio, 2014, 5, e01262-14.	4.1	20
42	Central Memory CD4+ T Cells Are Responsible for the Recombinant Bacillus Calmette-GuÃ©rin Î”ureC::hly Vaccine's Superior Protection Against Tuberculosis. Journal of Infectious Diseases, 2014, 210, 1928-1937.	4.0	112
43	<i>Mycobacterium tuberculosis</i>in the Proteomics Era. Microbiology Spectrum, 2014, 2, .	3.0	16
44	The Mtb Proteome Library: A Resource of Assays to Quantify the Complete Proteome of Mycobacterium tuberculosis. Cell Host and Microbe, 2013, 13, 602-612.	11.0	165
45	Improved Efficacy of Fosmidomycin against Plasmodium and Mycobacterium Species by Combination with the Cell-Penetrating Peptide Octaarginine. Antimicrobial Agents and Chemotherapy, 2013, 57, 4689-4698.	3.2	52
46	Reduced Drug Uptake in Phenotypically Resistant Nutrient-Starved Nonreplicating Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 1648-1653.	3.2	133
47	The Tuberculosis Vaccine Candidate Bacillus Calmette-GuÃ©rin Î”ureC::hly Coexpressing Human Interleukin-7 or -18 Enhances Antigen-Specific T Cell Responses in Mice. PLoS ONE, 2013, 8, e78966.	2.5	24
48	Nonclinical Development of BCG Replacement Vaccine Candidates. Vaccines, 2013, 1, 120-138.	4.4	29
49	Antigen 85C Inhibition Restricts Mycobacterium tuberculosis Growth through Disruption of Cord Factor Biosynthesis. Antimicrobial Agents and Chemotherapy, 2012, 56, 1735-1743.	3.2	62
50	Assembly of the Eukaryotic PLP-Synthase Complex from Plasmodium and Activation of the Pdx1 Enzyme. Structure, 2012, 20, 172-184.	3.3	26
51	Recombinant live vaccine candidates against tuberculosis. Current Opinion in Biotechnology, 2012, 23, 900-907.	6.6	68
52	<i>Mycobacterium tuberculosis</i>: success through dormancy. FEMS Microbiology Reviews, 2012, 36, 514-532.	8.6	571
53	Defining the structural requirements for ribose 5â€phosphateâ€binding and intersubunit crossâ€talk of the malarial pyridoxal 5â€phosphate synthase. FEBS Letters, 2010, 584, 4169-4174.	2.8	7
54	Vitamin B6 biosynthesis is essential for survival and virulence of Mycobacterium tuberculosis. Molecular Microbiology, 2010, 78, 980-988.	2.5	78

#	ARTICLE	IF	CITATIONS
55	Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. Microbiology (United Kingdom), 2010, 156, 81-87.	1.8	251
56	Biochemical and structural characterization of the putative dihydropteroate synthase ortholog Rv1207 of<i>Mycobacterium tuberculosis</i>. FEMS Microbiology Letters, 2008, 287, 128-135.	1.8	18
57	Vitamin B6 Biosynthesis by the Malaria Parasite Plasmodium falciparum. Journal of Biological Chemistry, 2006, 281, 3633-3641.	3.4	77
58	Mycobacterium tuberculosis in the Proteomics Era. , 0, , 239-260.		0